Why is Ligand repurchasing shares while issuing convertible debt?

Converting notes dilutes existing shareholders by adding new shares; the concurrent buyback is designed to offset that dilution by reducing the share count. This is a standard practice in convertible offerings to balance the interests of existing and new security holders.

Who will Ligand buy shares from in this repurchase?

The shares will be repurchased from certain purchasers of the convertible notes themselves, in privately negotiated transactions. This is different from open-market buybacks; Ligand is negotiating directly with some of the new debt investors.

What price will Ligand pay for the repurchased shares?

The repurchase price is expected to equal the last reported price of Ligand's common stock on the pricing date of the offering. This price is determined at the time the offering prices, not in advance.

Is the $75 million authorization binding, or could it be less?

The authorization is 'up to' $75 million, meaning Ligand is authorized to spend that amount but may repurchase fewer shares if it negotiates lower repurchase volumes with note purchasers. The actual spend depends on market conditions and buyer demand.

How does the hedge transaction relate to the share repurchase?

They are complementary but separate mechanisms. The hedge transactions with financial institutions use derivatives to reduce dilution; the share repurchase directly reduces share count. Together they work to limit the per-share dilution from note conversion.

LGNYZ 8-K Filed 2026-06-22 New authorization

Ligand authorizes up to $75M share repurchase tied to convertible note offering

Concurrent buyback intended to offset dilution from $550M convertible note issuance; privately negotiated transactions with note purchasers

Authorization$75M

MechanismPrivately negotiated transacti

What the filing says

Ligand Pharmaceuticals announced on June 22, 2026, its intention to offer $550 million in aggregate principal amount of convertible senior notes due 2031, with a 13-day greenshoe option for initial purchasers to buy up to an additional $82.5 million. As part of the transaction, Ligand expects to use up to $75 million of the net proceeds to repurchase shares of common stock from certain purchasers of the notes in privately negotiated transactions.

The share repurchase is designed to offset potential dilution to Ligand's common stock upon conversion of the notes. The buyback will be executed concurrently with the pricing of the offering through privately negotiated transactions effected through one of the initial purchasers or an affiliate thereof. The repurchase price per share is expected to equal the last reported price of Ligand's common stock as of the pricing date.

In addition to the direct share repurchase, Ligand expects to enter into convertible note hedge transactions and warrant transactions with financial institutions to further reduce potential dilution from note conversions. The company plans to use remaining net proceeds for general corporate purposes, including its previously announced acquisition of Xoma Royalty Corporation.

Ligand expects to use up to $75 million of the net proceeds from the offering to repurchase shares of its common stock from certain purchasers of the notes in privately negotiated transactions, as described below. Ligand intends to use the remaining net proceeds from the offering for general corporate purposes including investing in complementary businesses, companies, products and technologies. — LIGAND PHARMACEUTICALS INC 8-K filing · View on SEC EDGAR →

What this means

This authorization represents a defensive buyback component of a larger convertible debt issuance—a standard capital structure tactic where an issuer repurchases shares concurrently with convertible note offerings to mitigate shareholder dilution. The up-to-$75 million authorization is modest relative to the $550 million principal amount of the notes. The buyback will execute at market prices (the last reported price on pricing day) and targets selling note purchasers specifically, making this a privately negotiated transaction rather than open-market purchases. This structure allows Ligand to offset some conversion-related dilution while deploying capital flexibly as it pursues general corporate purposes and the Xoma Royalty acquisition.

Frequently asked questions

Why is Ligand repurchasing shares while issuing convertible debt?: Converting notes dilutes existing shareholders by adding new shares; the concurrent buyback is designed to offset that dilution by reducing the share count. This is a standard practice in convertible offerings to balance the interests of existing and new security holders.
Who will Ligand buy shares from in this repurchase?: The shares will be repurchased from certain purchasers of the convertible notes themselves, in privately negotiated transactions. This is different from open-market buybacks; Ligand is negotiating directly with some of the new debt investors.
What price will Ligand pay for the repurchased shares?: The repurchase price is expected to equal the last reported price of Ligand's common stock on the pricing date of the offering. This price is determined at the time the offering prices, not in advance.
Is the $75 million authorization binding, or could it be less?: The authorization is 'up to' $75 million, meaning Ligand is authorized to spend that amount but may repurchase fewer shares if it negotiates lower repurchase volumes with note purchasers. The actual spend depends on market conditions and buyer demand.
How does the hedge transaction relate to the share repurchase?: They are complementary but separate mechanisms. The hedge transactions with financial institutions use derivatives to reduce dilution; the share repurchase directly reduces share count. Together they work to limit the per-share dilution from note conversion.

authorization convertible-notes anti-dilution privately-negotiated capital-raise

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.